News Lilly’s Taltz scrapes win against Humira in psoriatic arthri... Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just.
News Amid tough competition, Novartis makes case for rheumatology... Swiss pharma hopes to bounce back from Q1 sales disappointment
News Novartis tests Cosentyx against Humira and biosimilars Trials will cover psoriatic arthritis and ankylosing spondylitis
News Pfizer's Xeljanz approved in psoriatic arthritis Xeljanz is first JAK inhibitor approved in psoriatic arthritis
Oncology BioNTech’s ASCO 2025 oncology advances: New data on bispecif... At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
